Radiotherapy trial quality assurance processes: a systematic review

Radio-Oncology

The use of master protocols for efficient trial design to evaluate radiotherapy interventions: a systematic review

J Natl Cancer Inst

Gilbert A, Samuel R, Cagney D, Sebag-Montefiore D, Brown J, Brown SR

doi: 10.1093/jnci/djae084

Further Publications

Systematic review of adoption, reporting and impact of health-related quality of life in phase III non-inferiority trials of systemic oncology treatments

Eur J Cancer

Notarnicola S, Zumstein L, Paparo J, Marandino L, Perrone F, Di Maio M

doi: 10.1016/j.ejca.2023.113374

Sarcoma

The challenge of running trials in advanced angiosarcoma: A systematic review of the literature from EORTC/STBSG to guide the development of angiosarcoma-specific trials

Eur J Cancer

Dufresne A, Lindner LH, Striefler J, Kasper B, Van Houdt W, Litiere S, Marreaud S, Blay JY, D'Ambrosio L, Stacchiotti S

doi: 10.1016/j.ejca.2024.114188

Further Publications

Postrecurrence Treatment in Neoadjuvant or Adjuvant FDA Registration Trials: A Systematic Review

JAMA Oncol

Olivier T, Haslam A, Prasad V

doi: 10.1001/jamaoncol.2024.1569

Further Publications

Dietary interventions in cancer: a systematic review of all randomized controlled trials

J Natl Cancer Inst

Ilerhunmwuwa NP, Abdul Khader AHS, Smith C, Cliff ERS, Booth CM, Rd EH, Aziz M, Lee-Smith W, Goodman A, Chakraborty R, Mohyuddin GR

doi: 10.1093/jnci/djae051

Lung, Respiratory and Thoracic Cancer

Accelerated hypofractionated radiotherapy for locally-advanced non-small cell lung cancer: A systematic review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee

J Thorac Oncol

Said BI, Geng Y, Badiyan SN, Bang A, Bezjak A, Chua KLM, Faivre-Finn C, Kong FM, Przybysz D, Putora PM, Munoz-Schuffenegger P, Siva S, Xu-Welliver M, McDonald F, Louie A, Chun SG

doi: 10.1016/j.jtho.2024.09.1437

Genitourinary Cancer

Ejaculatory function after radiotherapy for prostate cancer: a systematic review and meta-analysis

Prostate Cancer Prostatic Dis

Ghaffar U, Abbasi B, Li KD, Venishetty N, Hakam N, Fernandez A, Pearce R, Patel HV, Carlisle MN, Breyer BN

doi: 10.1038/s41391-024-00882-4

Multiple Myeloma (MM)

Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real-world evidence

Br J Haematol

Hartley-Brown MA, Weisel K, Bitetti J, Carter JA, McNamara S, Purser M, Palumbo A, Richardson PG

doi: 10.1111/bjh.19627

Further Publications

A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease

Eur J Cancer

Lopez-Olivo MA, Kachira JJ, Abdel-Wahab N, Pundole X, Aldrich JD, Carey P, Khan M, Geng Y, Pratt G, Suarez-Almazor ME

doi: 10.1016/j.ejca.2024.114148

Related content

The use of master protocols for efficient trial design to evaluate radiotherapy interventions: a systematic review

Systematic review of adoption, reporting and impact of health-related quality of life in phase III non-inferiority trials of systemic oncology treatments

The challenge of running trials in advanced angiosarcoma: A systematic review of the literature from EORTC/STBSG to guide the development of angiosarcoma-specific trials

Postrecurrence Treatment in Neoadjuvant or Adjuvant FDA Registration Trials: A Systematic Review

Dietary interventions in cancer: a systematic review of all randomized controlled trials

Accelerated hypofractionated radiotherapy for locally-advanced non-small cell lung cancer: A systematic review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee

Ejaculatory function after radiotherapy for prostate cancer: a systematic review and meta-analysis

Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real-world evidence

A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease